Clinical trial
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00238472 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 31, 2003
- Completion date
- June 30, 2005
- Enrollment
- 24
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.